Marilyn Dix Smith RPh, PhD, Founding Executive Director (1995-2014), Dr. Marilyn Dix Smith is Founding Executive Director of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). She has extensive experience in the management and financing of scientific organizations. She serves as Chief Executive Officer of the organization and is responsible for implementing the initiatives of the Society. Key initiatives developed, facilitated, or implemented by Dr. Smith are: ISPOR Research Digest (which contains over 27,500 scientific presentations from ISPOR meetings searchable by outcomes assessed, disease, and key words, and more), ISPOR Pharmacoeconomics Guidelines Around the World, ISPOR International Digest of Databases, ISPOR Good Research Practices (on subjects such as modeling, retrospective database, patient reported outcomes translation, cost-effectiveness analysis alongside clinical trials, use of real world data, budget impact, indirect treatment comparisons), Health Care Cost, Quality, and Outcomes: ISPOR Book of Terms (2003), Value in Health Special Issue: Moving the QALY Forward: Building a Pragmatic Road (2009), Value in Health Special Issue: Health Technology Assessment in Evidence-based Health Care Reimbursement Decisions Around the World: Lessons Learned (2009) and Medical Device and Diagnostic Device Outcomes Research (2011).
Dr. Smith has designed computer-assisted decision support system, which compares the costs and clinical outcomes of various disease treatment strategies. Dr. Smith has a breadth of experience in disease management, continuous quality improvement techniques, pharmacoeconomic applications, and health care provider and patient education.
Dr. Smith was Director, Managed Care Pharmacy, Lederle Laboratories. Earlier in her career at Lederle, Dr. Smith was Director, Quality Control, where she managed a staff of more than 150 professionals and associates, with responsibilities for assuring product quality. Her responsibilities included operations system design, validation and compliance. Dr. Smith was also Production Superintendent, supervising over 300 operation associates, where she was responsible for pharmaceutical product production.
Dr. Smith received her B.S. in Pharmacy and Ph.D. in Pharmaceutical Science from Ohio State University, and she has published many scientific articles, most recently in patient outcomes assessment and pharmacoeconomic analysis. She has authored many professional articles on disease cost-effective treatment and has given numerous presentations in quality assessment techniques, health care legislation, and disease treatment optimization. Dr. Smith was a Technical Review Consultant for the National Cancer Institute and held three 5-year terms on the Committee of Revision, United States Pharmacopoeia. She also was a co-founder of the American Association for Pharmaceutical Scientists, a non-profit scientific organization, and is a member of the American Society of Association Executives as well as many pharmacy and health care professional organizations.